Emactuzumab is under clinical development by SynOx Therapeutics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Emactuzumab’s likelihood of approval (LoA) and phase transition for Adenocarcinoma took place on 31 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 31 Oct 2022 increased Emactuzumab’s Phase Transition Success Rate (PTSR) for Brenner Tumor, increased LoA and PTSR for Epithelial Ovarian Cancer, increased LoA and PTSR for Fallopian Tube Cancer, increased LoA and PTSR for Peritoneal Cancer, and increased LoA and PTSR for Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Emactuzumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Emactuzumab (RG-7155, RO5509554) is under development for the treatment of solid tumors like metastatic pancreatic ductal adenocarcinoma, metastatic ovarian cancer, metastatic triple negative breast cancer, bladder cancer, gastric cancer, soft tissue sarcoma, colorectal cancer, pancreatic cancer, melanoma or malignant mesothelioma, tenosynovial giant cell tumor, pigmented villonodular synovitis and relapsed or refractory platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer clear cell adenocarcinoma, endometrioid adenocarcinoma, malignant Brenner's tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma, transitional cell carcinoma, undifferentiated carcinoma. The drug candidate is administered through intravenous route. It is a new molecular entity (NME). RG7155 acts on targeting colony stimulating factor-1 receptor (CSF-1R). It was also under development for treatment of relapsed or refractory follicular lymphoma.
SynOx Therapeutics overview
SynOx Therapeutics (SynOx) is a biopharmaceutical company. It develops emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (TGCT), also known as pigmented villonodular synovitis (PVNS) and other indications. SynOx is headquartered in Dublin, Ireland.
Quick View Emactuzumab LOA Data
|Highest Development Stage|